Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine

Draft scope (Pre-referral)

Draft remit/appraisal objective
To appraise the clinical and cost effectiveness of botulinum toxin type A within its licensed indication for the prophylaxis of headaches associated with chronic migraine.

Background
Migraine is primarily a headache disorder manifesting as recurring attacks usually lasting for 4–72 hours involving throbbing head pain of moderate to severe intensity. It is often accompanied by nausea, sometimes vomiting, sensitivity to light, sensitivity to sound, and/or other sensory stimuli. Some people can have warning symptoms called an aura, before the start of a headache. Factors that can trigger attacks in people susceptible to migraines include stress, change in sleep pattern, overtiredness, consumption of caffeine or alcohol, climatic conditions and use of visual display units.

Chronic migraine is defined by the International Headache Society as the occurrence of headaches on 15 days or more per month for at least 3 months where the attacks fulfil criteria for pain and associated symptoms of migraine without aura on at least 8 days per month for at least 3 months, where there is no medication overuse, and where the headaches are not attributable to another causative disorder. To fulfil the criteria for chronic migraine, a person must previously have had at least five attacks fulfilling the International Headache Society’s criteria for migraine without aura.

It is estimated that there are 190,000 migraine attacks experienced every day in England and 6 million people suffer from migraine in the UK. Prevalence has been reported to be 5–25% in women and 2–10% in men.

Preventive (also called prophylactic) treatment of migraines can be an important component of migraine management. The goals of preventive therapy are to reduce the frequency, painfulness, and/or duration of migraines, and to increase the effectiveness of medication that is taken at the earliest signs of a migraine headache (known as abortive therapy). Preventative treatment of migraines may also help to avoid medication overuse headache, otherwise known as rebound headache, which is linked to overuse of pain medications, and is a common problem among people with migraines.
Preventative interventions can take many forms including nutritional supplements, lifestyle alterations such as increased exercise and avoidance of migraine triggers, and prophylactic migraine medications. Prophylactic migraine medications are generally considered for people who have at least two attacks a month, whose attacks are increasing in frequency, whose attacks cause significant disability despite abortive treatment, or who cannot take abortive treatment for migraine attacks. Prophylactic migraine medications include betablockers (propranolol, atenolol, metoprolol, nadolol and timolol), valproic acid, sodium valproate, topiramate, amitriptyline, pizotifen, gabapentin and cyproheptadine.

**The technology**

Botulinum toxin type A (Botox, Allergan) is a purified neurotoxin complex which produces seven neurotoxins that are structurally similar but immunologically distinct, and has neuromuscular transmitter blocking effects.

Botulinum toxin type A has a UK marketing authorisation for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). It is administered by intramuscular injection to between 31 and 39 sites around the head and back of the neck. Repeated treatments are recommended every 12 weeks.

<table>
<thead>
<tr>
<th>Intervention(s)</th>
<th>Botulinum toxin type A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population(s)</strong></td>
<td>Adults with headaches on at least 15 days per month of which at least 8 days are associated with chronic migraine</td>
</tr>
<tr>
<td><strong>Comparators</strong></td>
<td>Standard management without botulinum toxin type A</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>The outcome measures to be considered include:</td>
</tr>
<tr>
<td></td>
<td>- frequency, duration and intensity of migraine-related headaches</td>
</tr>
<tr>
<td></td>
<td>- adverse effects of treatment</td>
</tr>
<tr>
<td></td>
<td>- health-related quality of life.</td>
</tr>
<tr>
<td><strong>Economic analysis</strong></td>
<td>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</td>
</tr>
<tr>
<td></td>
<td>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</td>
</tr>
<tr>
<td></td>
<td>Costs will be considered from an NHS and Personal</td>
</tr>
</tbody>
</table>
Social Services perspective.

<table>
<thead>
<tr>
<th>Other considerations</th>
<th>Guidance will only be issued in accordance with the marketing authorisation.</th>
</tr>
</thead>
</table>
| Related NICE recommendations | Related Guidelines:  
Related Interventional Procedures:  
Interventional Procedure Guidance No. 370, Dec 2010, ‘Percutaneous closure of patent foramen ovale for recurrent migraine’ Review date tbc |

### Questions for consultation

Is the population appropriately defined?

Where is botulinum toxin type A likely to be positioned in the current clinical pathway for the prophylaxis of headaches associated with chronic migraine?

Has the most appropriate comparator for botulinum toxin type A for the prophylaxis of headaches associated with chronic migraine been included in the scope? How should standard management be defined?

Have the most appropriate outcomes for the prophylaxis of headaches associated with chronic migraine been included in the scope? Are there any additional outcomes which should be included?

Are there any subgroups of people in whom the technology is expected to be more clinically effective and cost effective or other groups that should be examined separately? For example, subgroups of people based on their experience of aura, or based on the level of use of headache and/or migraine medication?

Please consider whether in the remit or the scope there are any issues relevant to equality. Please pay particular attention to whether changes need to be made to the remit or scope in order to promote equality, eliminate unlawful discrimination, or foster good relations between people who share a characteristic protected by the equalities legislation and those who do not share it, or if there is information that could be collected during the assessment process which would enable NICE to take account of equality issues when developing guidance.

Do you consider the technology to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might
improve the way that current need is met (is this a ‘step-change’ in the management of the condition)?

Do you consider that the use of the technology can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.

NICE intends to appraise this technology through its Single Technology Appraisal (STA) Process. We welcome comments on the appropriateness of appraising this topic through this process. (Information on the Institute’s Technology Appraisal processes is available at http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/technology_appraisal_process_guides.jsp)